PCL, Inc. (KOSDAQ:241820)

South Korea · Delayed Price · Currency is KRW

302.00

-5.00 (-1.63%)

Mar 21, 2025, 5:32 PM KST

-98.95% (1Y)

Market Cap	17.87B -76.9%
Revenue (ttm)	4.98B -36.8%
Net Income	-47.06B
EPS	-14,020.37
Shares Out	2.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,458
Open	307.00
Previous Close	307.00
Day's Range	300.00 - 307.00
52-Week Range	300.00 - 43,800.00
Beta	1.21
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2026

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2008

Employees 31

Stock Exchange KOSDAQ

Ticker Symbol 241820

Full Company Profile

Financial Performance

In 2024, PCL, Inc.'s revenue was 1.25 billion, a decrease of -85.22% compared to the previous year's 8.43 billion. Losses were -52.34 billion, 157.6% more than in 2023.

Financial Statements